Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in melanoma genetics.

N Hayward1

  • 1Joint Experimental Oncology Programme of the Queensland Institute of Medical Research, University of Queensland and the Queensland Cancer Fund, PO Royal Brisbane Hospital, QLD 4029, Australia. nickH@qimr.edu.au

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metastatic osteosarcoma tumor thrombus in a Cavalier King Charles Spaniel presenting with dyspnea.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2022
Same author

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.

British journal of cancer·2011
Same author

Vascular changes in epilepsy: functional consequences and association with network plasticity in pilocarpine-induced experimental epilepsy.

Neuroscience·2009
Same author

Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway.

Molecular psychiatry·2007
Same author

Mutation of the tumour suppressor p33ING1b is rare in melanoma.

The British journal of dermatology·2006
Same author

Identification of the semaphorin receptor PLXNA2 as a candidate for susceptibility to schizophrenia.

Molecular psychiatry·2006

Genetic research reveals new melanoma risk factors. Variants in the CDKN2A gene, including those in untranslated regions (UTRs), impact predisposition and familial risk, aiding in identifying individuals needing screening.

Area of Science:

  • Genetics and Genomics
  • Dermatology
  • Cancer Research

Background:

  • Genetic susceptibility plays a crucial role in melanoma development.
  • Recent research has focused on non-coding regions of key genes.
  • The CDKN2A gene is a significant locus for melanoma predisposition.

Purpose of the Study:

  • To elucidate the role of variants outside the coding region of the CDKN2A gene in melanoma predisposition.
  • To understand how specific mutations and polymorphisms in CDKN2A's untranslated regions (UTRs) affect gene expression and cancer risk.
  • To evaluate the clinical implications of CDKN2A variants for risk assessment and screening strategies.

Main Methods:

  • Characterization of genetic variants in the 5' and 3' untranslated regions (UTRs) of the CDKN2A gene.

Related Experiment Videos

  • Assessment of the functional impact of a 5' UTR mutation on p16 expression via novel upstream initiation.
  • Analysis of the association between a 3' UTR polymorphism and familial melanoma risk.

    • Main Results:

    • A mutation in the 5' UTR of CDKN2A was identified, creating an upstream initiation codon that abrogates p16 expression.
    • A common polymorphism in the 3' UTR of CDKN2A is significantly associated with increased familial risk of melanoma.
    • Previous studies linking CDKN2A mutation status to non-melanoma cancers, atypical nevi, and multiple primary melanomas are further contextualized.

    Conclusions:

    • Variants in the untranslated regions of CDKN2A are important determinants of melanoma susceptibility.
    • These findings enhance our understanding of the genetic architecture of melanoma.
    • Identifying individuals with these specific CDKN2A variants can improve targeted screening and risk management strategies for melanoma.